Compare MRBK & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRBK | BNR |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.3M | 252.7M |
| IPO Year | 2018 | 2019 |
| Metric | MRBK | BNR |
|---|---|---|
| Price | $20.17 | $20.64 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 119.3K | 33.1K |
| Earning Date | 04-28-2026 | 06-05-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | ★ 30.34 | N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $6,316,000.00 | N/A |
| Revenue This Year | $25.40 | $111.65 |
| Revenue Next Year | $8.15 | N/A |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $11.17 | $2.18 |
| 52 Week High | $21.59 | $41.72 |
| Indicator | MRBK | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 54.25 |
| Support Level | $18.32 | $19.72 |
| Resistance Level | $20.86 | $23.80 |
| Average True Range (ATR) | 0.54 | 1.45 |
| MACD | 0.03 | 0.76 |
| Stochastic Oscillator | 51.25 | 76.52 |
Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.